# First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

> **NCT02896231** · PHASE1 · COMPLETED · sponsor: **Beijing Pearl Biotechnology Limited Liability Company** · enrollment: 37 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** PLB1001

## Key facts

- **NCT ID:** NCT02896231
- **Lead sponsor:** Beijing Pearl Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896231, "First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02896231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*